Foghorn Therapeutics (FHTX) Equity Ratio (2019 - 2026)

Foghorn Therapeutics' Equity Ratio history runs 8 years deep, the most recent figure standing at 0.34 for Q1 2026.

• In Q1 2026, Equity Ratio fell 44.31% year-over-year to 0.34; the TTM figure through Mar 2026 stood at 0.34 (down 44.31% YoY), while the FY2025 annual figure was 0.55, down 241.63% from the prior year.
• Equity Ratio was 0.34 for Q1 2026 at Foghorn Therapeutics, up from 0.55 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.15 in Q1 2022 to a low of 0.55 in Q4 2025.
• Historically, Equity Ratio has averaged 0.17 across 5 years, with a median of 0.16 in 2024.
• The sharpest annual moves came in 2023 and 2024: Equity Ratio plunged 97696.47% in 2023, then jumped 70.01% in 2024.
• A 5-year view of Equity Ratio shows it stood at 0.0 in 2022, then slumped by 97696.47% to 0.27 in 2023, then soared by 40.62% to 0.16 in 2024, then tumbled by 241.63% to 0.55 in 2025, then surged by 37.21% to 0.34 in 2026.
• The last three Equity Ratio figures came in at 0.34 (Q1 2026), 0.55 (Q4 2025), and 0.44 (Q3 2025), per Business Quant data.